<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD12010000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P05121</UniProt_ID>
  <Seq_Length>402</Seq_Length>
  <Molecule_Weight>45060</Molecule_Weight>
  <KEGG_ID>hsa:5054</KEGG_ID>
  <Orthology_ID>K03982</Orthology_ID>
  <EBI_ID>EBI-953978</EBI_ID>
  <Function_Summary>Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.</Function_Summary>
  <Pfam_ID>PF00079:Serpin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>3</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Serpin E1</Alias>
      <Alias>PAI</Alias>
      <Alias>Endothelial plasminogen activator inhibitor</Alias>
      <Alias>PAI-1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Stops, prevents or reduces the activity of serine-type endopeptidases, enzymes that catalyze the hydrolysis of nonterminal peptide bonds in a polypeptide chain; a serine residue (and a histidine residue) are at the active center of the enzyme.</Detail>
      <Keyword>Serine-type endopeptidase inhibitor activity</Keyword>
      <Ontology_ID>GO:0004867</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protease or peptidase.</Detail>
      <Keyword>Protease binding</Keyword>
      <Ontology_ID>GO:0002020</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.</Detail>
      <Keyword>Receptor binding</Keyword>
      <Ontology_ID>GO:0005102</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Stops, prevents or reduces the activity of a peptidase, any enzyme that catalyzes the hydrolysis peptide bonds.</Detail>
      <Keyword>Peptidase inhibitor activity</Keyword>
      <Ontology_ID>GO:0030414</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of smooth muscle cell migration.</Detail>
      <Keyword>Negative regulation of smooth muscle cell migration</Keyword>
      <Ontology_ID>GO:0014912</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an extracellular matrix.</Detail>
      <Keyword>Extracellular matrix organization</Keyword>
      <Ontology_ID>GO:0030198</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the frequency, rate or extent of endopeptidase activity, the endohydrolysis of peptide bonds within proteins.</Detail>
      <Keyword>Negative regulation of endopeptidase activity</Keyword>
      <Ontology_ID>GO:0010951</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency, or extent of blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to damaged vasculature.</Detail>
      <Keyword>Negative regulation of vascular wound healing</Keyword>
      <Ontology_ID>GO:0061044</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency or extent of the synthesis or release of any leukotriene following a stimulus as part of an inflammatory response.</Detail>
      <Keyword>Positive regulation of leukotriene production involved in inflammatory response</Keyword>
      <Ontology_ID>GO:0035491</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form.</Detail>
      <Keyword>Gene expression</Keyword>
      <Ontology_ID>GO:0010467</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The regulated exocytosis of secretory granules containing preformed mediators such as histamine and serotonin by a platelet.</Detail>
      <Keyword>Platelet degranulation</Keyword>
      <Ontology_ID>GO:0002576</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury.</Detail>
      <Keyword>Negative regulation of wound healing</Keyword>
      <Ontology_ID>GO:0061045</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Reactions triggered in response to the presence of a Gram-negative bacterium that act to protect the cell or organism.</Detail>
      <Keyword>Defense response to Gram-negative bacterium</Keyword>
      <Ontology_ID>GO:0050829</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of interleukin-8 production.</Detail>
      <Keyword>Positive regulation of interleukin-8 production</Keyword>
      <Ontology_ID>GO:0032757</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of RNA on a template of DNA.</Detail>
      <Keyword>Transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0006351</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.</Detail>
      <Keyword>Cellular response to lipopolysaccharide</Keyword>
      <Ontology_ID>GO:0071222</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate, or extent of cell adhesion mediated by integrin.</Detail>
      <Keyword>Negative regulation of cell adhesion mediated by integrin</Keyword>
      <Ontology_ID>GO:0033629</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any biological process in an organism that recurs with a regularity of approximately 24 hours.</Detail>
      <Keyword>Circadian rhythm</Keyword>
      <Ontology_ID>GO:0007623</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of plasminogen activation. Plasminogen activation is the process in which plasminogen is processed to plasmin.</Detail>
      <Keyword>Negative regulation of plasminogen activation</Keyword>
      <Ontology_ID>GO:0010757</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport.</Detail>
      <Keyword>Positive regulation of receptor-mediated endocytosis</Keyword>
      <Ontology_ID>GO:0048260</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate, or extent of monocyte chemotaxis.</Detail>
      <Keyword>Positive regulation of monocyte chemotaxis</Keyword>
      <Ontology_ID>GO:0090026</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of receptor activity. Receptor activity is when a molecule combines with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Regulation of receptor activity</Keyword>
      <Ontology_ID>GO:0010469</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of smooth muscle cell-matrix adhesion.</Detail>
      <Keyword>Negative regulation of smooth muscle cell-matrix adhesion</Keyword>
      <Ontology_ID>GO:2000098</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a transforming growth factor beta receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Transforming growth factor beta receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0007179</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An ongoing process that solubilizes fibrin, chiefly by the proteolytic action of plasmin, resulting in the removal of small blood clots.</Detail>
      <Keyword>Fibrinolysis</Keyword>
      <Ontology_ID>GO:0042730</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of cell proliferation.</Detail>
      <Keyword>Regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0042127</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process associated with progression of the cell from its inception to the end of its lifespan that occurs when the cell is in a non-dividing, or quiescent, state.</Detail>
      <Keyword>Chronological cell aging</Keyword>
      <Ontology_ID>GO:0001300</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the inflammatory response.</Detail>
      <Keyword>Positive regulation of inflammatory response</Keyword>
      <Ontology_ID>GO:0050729</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell apoptosis.</Detail>
      <Keyword>Negative regulation of endothelial cell apoptosis</Keyword>
      <Ontology_ID>GO:2000352</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases angiogenesis.</Detail>
      <Keyword>Positive regulation of angiogenesis</Keyword>
      <Ontology_ID>GO:0045766</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of blood coagulation.</Detail>
      <Keyword>Positive regulation of blood coagulation</Keyword>
      <Ontology_ID>GO:0030194</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell migration.</Detail>
      <Keyword>Negative regulation of cell migration</Keyword>
      <Ontology_ID>GO:0030336</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.</Detail>
      <Keyword>Negative regulation of fibrinolysis</Keyword>
      <Ontology_ID>GO:0051918</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of blood coagulation.</Detail>
      <Keyword>Negative regulation of blood coagulation</Keyword>
      <Ontology_ID>GO:0030195</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.</Detail>
      <Keyword>Angiogenesis</Keyword>
      <Ontology_ID>GO:0001525</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPYGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAIFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAVDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPDGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPKFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASSSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</Protein_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Plasma�</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Platelet alpha granule lumen</CellLocal>
      <Ontology_ID>GO:0031093</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular vesicular exosome</CellLocal>
      <Ontology_ID>GO:0070062</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular matrix</CellLocal>
      <Ontology_ID>GO:0031012</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>SERPINE1</Gene_Name>
    <Gene_Alias>PAI1; PLANH1</Gene_Alias>
    <Gene_ID>5054</Gene_ID>
    <Genbank_ACCN>NM_000602</Genbank_ACCN>
    <Protein_ACCN>NP_000593</Protein_ACCN>
    <HGNC_ID>8583</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5054</Gene_URL>
    <UCSC_ID>uc003uxt.4</UCSC_ID>
    <EMBL_ID>ENSG00000106366</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P02763</Uniprot_ID>
      <Gene_Name>ORM1</Gene_Name>
      <EBI_ID>EBI-976767</EBI_ID>
      <PPI_EBI_URL>EBI-953978,EBI-976767</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Coronary Thrombosis</Disease_Name>
      <Disease_Detail>Coronary Thrombosis</Disease_Detail>
      <Disease_DB>CRN017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/coronary_thrombosis?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myocardial Infarction</Disease_Name>
      <Disease_Detail>Myocardial Infarction</Disease_Detail>
      <Disease_DB>MYC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myocardial_infarction?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Central Retinal Vein Occlusion</Disease_Name>
      <Disease_Detail>Central Retinal Vein Occlusion</Disease_Detail>
      <Disease_DB>CNT016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/central_retinal_vein_occlusion?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Coronary Restenosis</Disease_Name>
      <Disease_Detail>Coronary Restenosis</Disease_Detail>
      <Disease_DB>CRN020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/coronary_restenosis?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Central Retinal Artery Occlusion</Disease_Name>
      <Disease_Detail>Central Retinal Artery Occlusion</Disease_Detail>
      <Disease_DB>CNT028</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/central_retinal_artery_occlusion?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Catastrophic Antiphospholipid Syndrome</Disease_Name>
      <Disease_Detail>Catastrophic Antiphospholipid Syndrome</Disease_Detail>
      <Disease_DB>CTS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/catastrophic_antiphospholipid_syndrome?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carotid Artery Thrombosis</Disease_Name>
      <Disease_Detail>Carotid Artery Thrombosis</Disease_Detail>
      <Disease_DB>CRT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carotid_artery_thrombosis?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Transcription of Plasminogen Activator Inhibitor, Modulator of</Disease_Name>
      <Disease_Detail>Transcription of Plasminogen Activator Inhibitor, Modulator of</Disease_Detail>
      <Disease_DB>TRN039</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transcription_of_plasminogen_activator_inhibitor_modulator_of?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Paranasal Sinus Disease</Disease_Name>
      <Disease_Detail>Paranasal Sinus Disease</Disease_Detail>
      <Disease_DB>PRN021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/paranasal_sinus_disease?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2 Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>TYP009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2_diabetes_mellitus?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Metabolic Syndrome X</Disease_Name>
      <Disease_Detail>Metabolic Syndrome X</Disease_Detail>
      <Disease_DB>MTB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/metabolic_syndrome_x?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Plasminogen Activator Inhibitor Type 1 Deficiency</Disease_Name>
      <Disease_Detail>Plasminogen Activator Inhibitor Type 1 Deficiency</Disease_Detail>
      <Disease_DB>PLS018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/plasminogen_activator_inhibitor_type_1_deficiency?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hepatic Vein Thrombosis</Disease_Name>
      <Disease_Detail>Hepatic Vein Thrombosis</Disease_Detail>
      <Disease_DB>HPT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hepatic_vein_thrombosis?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Inferior Vena Cava Interruption</Disease_Name>
      <Disease_Detail>Inferior Vena Cava Interruption</Disease_Detail>
      <Disease_DB>INF133</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/inferior_vena_cava_interruption?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thromboembolism</Disease_Name>
      <Disease_Detail>Thromboembolism</Disease_Detail>
      <Disease_DB>THR079</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thromboembolism?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Protein S Deficiency</Disease_Name>
      <Disease_Detail>Protein S Deficiency</Disease_Detail>
      <Disease_DB>PRT014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/protein_s_deficiency?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carotid Intimal Medial Thickness</Disease_Name>
      <Disease_Detail>Carotid Intimal Medial Thickness</Disease_Detail>
      <Disease_DB>CRT018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carotid_intimal_medial_thickness?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neonatal Stroke</Disease_Name>
      <Disease_Detail>Neonatal Stroke</Disease_Detail>
      <Disease_DB>NNT024</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neonatal_stroke?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pre-Eclampsia</Disease_Name>
      <Disease_Detail>Pre-Eclampsia</Disease_Detail>
      <Disease_DB>PRC016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pre_eclampsia?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vascular Disease</Disease_Name>
      <Disease_Detail>Vascular Disease</Disease_Detail>
      <Disease_DB>VSC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vascular_disease?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Angiodysplasia</Disease_Name>
      <Disease_Detail>Angiodysplasia</Disease_Detail>
      <Disease_DB>ANG011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/angiodysplasia?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Renal Fibrosis</Disease_Name>
      <Disease_Detail>Renal Fibrosis</Disease_Detail>
      <Disease_DB>RNL077</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/renal_fibrosis?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amaurosis Fugax</Disease_Name>
      <Disease_Detail>Amaurosis Fugax</Disease_Detail>
      <Disease_DB>AMR003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amaurosis_fugax?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombophilia</Disease_Name>
      <Disease_Detail>Thrombophilia</Disease_Detail>
      <Disease_DB>THR015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombophilia?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Meningococcemia</Disease_Name>
      <Disease_Detail>Meningococcemia</Disease_Detail>
      <Disease_DB>MNN021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/meningococcemia?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ischemic Colitis</Disease_Name>
      <Disease_Detail>Ischemic Colitis</Disease_Detail>
      <Disease_DB>ISC015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ischemic_colitis?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atherosclerosis</Disease_Name>
      <Disease_Detail>Atherosclerosis</Disease_Detail>
      <Disease_DB>ATH003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atherosclerosis?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin Resistance</Disease_Name>
      <Disease_Detail>Insulin Resistance</Disease_Detail>
      <Disease_DB>INS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_resistance?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Central Serous Chorioretinopathy</Disease_Name>
      <Disease_Detail>Central Serous Chorioretinopathy</Disease_Detail>
      <Disease_DB>CNT060</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/central_serous_chorioretinopathy?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Eclampsia</Disease_Name>
      <Disease_Detail>Eclampsia</Disease_Detail>
      <Disease_DB>ECL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/eclampsia?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Retinal Artery Occlusion</Disease_Name>
      <Disease_Detail>Retinal Artery Occlusion</Disease_Detail>
      <Disease_DB>RTN014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/retinal_artery_occlusion?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Meckel's Diverticulum</Disease_Name>
      <Disease_Detail>Meckel's Diverticulum</Disease_Detail>
      <Disease_DB>MCK002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/meckels_diverticulum?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thromboangiitis Obliterans</Disease_Name>
      <Disease_Detail>Thromboangiitis Obliterans</Disease_Detail>
      <Disease_DB>THR006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thromboangiitis_obliterans?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Legg-Calve-Perthes Disease</Disease_Name>
      <Disease_Detail>Legg-Calve-Perthes Disease</Disease_Detail>
      <Disease_DB>LGG001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/legg_calve_perthes_disease?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chronic Angina</Disease_Name>
      <Disease_Detail>Chronic Angina</Disease_Detail>
      <Disease_DB>CHR476</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chronic_angina?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetic Angiopathy</Disease_Name>
      <Disease_Detail>Diabetic Angiopathy</Disease_Detail>
      <Disease_DB>DBT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetic_angiopathy?search=SERPINE1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of plasminogen activator inhibitor-1 in a metastable active conformation.</PDB_Title>
      <PDB_ID>3Q02</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q02</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.</PubMed_Title>
      <Author>Jensen, J.K., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:29709-29717</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21697084?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CLEAVED SUBSTRATE VARIANT OF PLASMINOGEN ACTIVATOR INHIBITOR-1</PDB_Title>
      <PDB_ID>9PAI</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=9PAI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1.</PubMed_Title>
      <Author>Aertgeerts, K., et al.</Author>
      <Journal>Nat.Struct.Biol.(1995)2:891-897</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7552714?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PLASMINOGEN ACTIVATOR INHIBITOR-1</PDB_Title>
      <PDB_ID>1C5G</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C5G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition.</PubMed_Title>
      <Author>Tucker, H.M., et al.</Author>
      <Journal>Nat.Struct.Biol.(1995)2:442-445</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7664104?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ACTIVE FORM OF HUMAN PAI-1</PDB_Title>
      <PDB_ID>1DVM</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of active and latent PAI-1: a possible stabilizing role for chloride ions.</PubMed_Title>
      <Author>Stout, T.J., et al.</Author>
      <Journal>Biochemistry(2000)39:8460-8469</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10913251?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human very long half life Plasminogen Activator Inhibitor type-1</PDB_Title>
      <PDB_ID>3R4L</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3R4L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.</PubMed_Title>
      <Author>Jankun, J., et al.</Author>
      <Journal>Int.J.Mol.Med.(2012)29:61-64</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21947232?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF NATIVE PLASMINOGEN ACTIVATOR INHIBITOR-1</PDB_Title>
      <PDB_ID>1DB2</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DB2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.</PubMed_Title>
      <Author>Nar, H., et al.</Author>
      <Journal>J.Mol.Biol.(2000)297:683-695</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10731421?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of a novel small molecule inactivator bound to plasminogen activator inhibitor-1</PDB_Title>
      <PDB_ID>4G8R</PDB_ID>
      <Resolution>2.19</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4G8R</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD05872047</ASD_Ligand>
      <PubMed_Title>Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.</PubMed_Title>
      <Author>Li, S.H., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2013)110:E4941-E4949</Journal>
      <PubMed_ID>24297881</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>High resolution structure of a stable Plasminogen activator inhibitor type-1 in its protease cleaved form</PDB_Title>
      <PDB_ID>3CVM</PDB_ID>
      <Resolution>2.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CVM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.</PubMed_Title>
      <Author>Jensen, J.K., et al.</Author>
      <Journal>Protein Sci.(2008)17:1844-1849</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18725454?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of a Michaelis Complex between Plasminogen Activator Inhibitor-1 and Urokinase-type Plasminogen Activator</PDB_Title>
      <PDB_ID>3PB1</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PB1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.</PubMed_Title>
      <Author>Lin, Z., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:7027-7032</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21199867?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 IN COMPLEX WITH A PENTAPEPTIDE</PDB_Title>
      <PDB_ID>1A7C</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A7C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide</PubMed_Title>
      <Author>Xue, Y., et al.</Author>
      <Journal>Structure(1998)6:627-636</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9634700?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PLASMINOGEN ACTIVATOR INHIBITOR-1 COMPLEX WITH SOMATOMEDIN B DOMAIN OF VITRONECTIN</PDB_Title>
      <PDB_ID>1OC0</PDB_ID>
      <Resolution>2.28</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OC0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>How Vitronectin Binds Pai-1 to Modulate Fibrinolysis and Cell Migration</PubMed_Title>
      <Author>Zhou, A., et al.</Author>
      <Journal>Nat.Struct.Biol.(2003)10:541</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12808446?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of plasminogen activator inhibitor-1 in a metastable active conformation.</PDB_Title>
      <PDB_ID>3Q03</PDB_ID>
      <Resolution>2.64</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q03</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.</PubMed_Title>
      <Author>Jensen, J.K., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:29709-29717</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21697084?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LATENT FORM OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)</PDB_Title>
      <PDB_ID>1DVN</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of active and latent PAI-1: a possible stabilizing role for chloride ions.</PubMed_Title>
      <Author>Stout, T.J., et al.</Author>
      <Journal>Biochemistry(2000)39:8460-8469</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10913251?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>High quality structure of cleaved PAI-1-stab</PDB_Title>
      <PDB_ID>3EOX</PDB_ID>
      <Resolution>2.61</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EOX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High quality structure of cleaved PAI-1-stab.</PubMed_Title>
      <Author>Dewilde, M., et al.</Author>
      <Journal>J.Struct.Biol.(2009)165:126-132</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19059484?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of a novel small molecule inactivator bound to plasminogen activator inhibitor-1</PDB_Title>
      <PDB_ID>4G8O</PDB_ID>
      <Resolution>2.71</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4G8O</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD05872047</ASD_Ligand>
      <PubMed_Title>Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.</PubMed_Title>
      <Author>Li, S.H., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2013)110:E4941-E4949</Journal>
      <PubMed_ID>24297881</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Plasminogen activator inhibitor-1</PDB_Title>
      <PDB_ID>1B3K</PDB_ID>
      <Resolution>2.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1B3K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.</PubMed_Title>
      <Author>Sharp, A.M., et al.</Author>
      <Journal>Structure Fold.Des.(1999)7:111-118</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10368279?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PAI-1 in Complex with Gallate</PDB_Title>
      <PDB_ID>4IC0</PDB_ID>
      <Resolution>2.32</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4IC0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of PAI-1 in Complex with Gallate</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>A novel PAI-I inhibitor and its structural mechanism</PDB_Title>
      <PDB_ID>3UT3</PDB_ID>
      <Resolution>2.42</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3UT3</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD12010003</ASD_Ligand>
      <PubMed_Title>A novel PAI-I inhibitor and its structural mechanism</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Plasminogen activator inhibitor type-1 in complex with the inhibitor AZ3976</PDB_Title>
      <PDB_ID>4AQH</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4AQH</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD12010002</ASD_Ligand>
      <PubMed_Title>Characterization of a Small Molecule Inhibitor of Plasminogen Activator Inhibitor Type 1 that Accelerates the Transition Into the Latent Conformation</PubMed_Title>
      <Author>Fjellstrom, O., et al.</Author>
      <Journal>J.Biol.Chem.(2013)288:873</Journal>
      <PubMed_ID>23155046</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1.8A Resolution Structure of Latent Plasminogen Activator Inhibitor-1(PAI-1)</PDB_Title>
      <PDB_ID>1LJ5</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LJ5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The PDB archive contains information about experimentally-determined structures of proteins, nucleic acids, and complex assemblies. As a member of the wwPDB, the RCSB PDB curates and annotates PDB data according to agreed upon standards. The RCSB PDB also provides a variety of tools and resources. Users can perform simple and advanced searches based on annotations relating to sequence, structure and function. These molecules are visualized, downloaded, and analyzed by users who range from students to specialized scientists.</PubMed_Title>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05142</Pathway_ID>
      <Pathway_Title>Chagas disease (American trypanosomiasis)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04115</Pathway_ID>
      <Pathway_Title>p53 signaling pathway</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04390</Pathway_ID>
      <Pathway_Title>Hippo signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.f.b.b.b.h.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta </CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1a7c</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <PDB_ID>3UT3;4AQH;4G8O;4G8R</PDB_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD05872047</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD12010002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD12010003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2015-04-08</Create_Date>
</Organism_Record>